Results 141 to 150 of about 783,471 (282)

Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6 ‐Mediated Drug–Drug–Gene Interactions of Venlafaxine in Koreans

Clinical and Translational Science
ABSTRACT CYP2D6‐mediated drug–drug–gene interactions (DDGIs) are known to influence the pharmacokinetics of venlafaxine and its metabolism to O‐desmethylvenlafaxine. Solanidine and 3,4‐seco‐solanidine‐3,4‐dioic acid (SSDA) have recently been investigated as candidate endogenous CYP2D6 biomarkers; however, they remain unexplored in ...
Sungyeun Bae, Ga‐Yeong Lee, Eunsol Yang, Woori Chae, Kyung‐Sang Yu, Joo‐Youn Cho, Anhye Kim, Namyi Gu, SeungHwan Lee   +8 more
openaire   +1 more source

Additional file 9 of Multimorbidity, polypharmacy, and drug-drug-gene interactions following a non-ST elevation acute coronary syndrome: analysis of a multicentre observational study

, 2020
Additional file 9. Table of identified substantial interactions.
Turner, R. M., de Koning, E. M., Fontana, V., Thompson, A., Pirmohamed, M.   +4 more
openaire   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma

Molecular Oncology, EarlyView.
Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski, Júlia Perera‐Bel, Alejo Rodriguez‐Vida, Nuria Juanpere, Jihyun Lee, Daniel E. Michaud, Jennifer L. Guerriero, Kent W. Mouw, Aristotelis Bamias, Filipe L. F. Carvalho, Joaquim Bellmunt   +10 more
wiley   +1 more source

Drug-induced gingival overgrowth: FAERS based real-world pharmacovigilance study and network pharmacology analysis

Frontiers in Pharmacology
BackgroundDrug-induced gingival overgrowth (DIGO) as an interdisciplinary clinical challenge, faces dual therapeutic barriers due to its unclear pathogenesis and high recurrence rate, forcing clinicians to balance therapeutic benefits against oral ...
Qingxia Zhu, Qingxia Zhu, Zebing Wu, Zebing Wu, Xianting Jiao, Lu Han, Lu Han, Yongfang Yuan, Yongfang Yuan   +8 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

An ADR pharmaceutical care for severe gastrointestinal bleeding of rivaroxaban in a patient with nonvalvular atrial fibrillation based on TDM and genetic testing: a case report

BMC Medical Genomics
Background Due to its predictable pharmacodynamics and pharmacokinetics, stable blood concentration, and relatively short half-life, rivaroxaban is widely used in the prevention and treatment of thrombosis.
Youqi Huang, Hongjin Gao, Mingyu Chen, Yuze Lin, Huiting Liu, Min Chen   +5 more
doaj   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Novel artificial intelligence-based identification of drug-gene-disease interaction using protein-protein interaction

BMC Bioinformatics
The evaluation of drug-gene-disease interactions is key for the identification of drugs effective against disease. However, at present, drugs that are effective against genes that are critical for disease are difficult to identify.
Y.-h Taguchi, Turki Turki
doaj   +1 more source

Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme

, 1998
The low molecular weight protein (LMWP) lysozyme is a suitable drug carrier for renal drug targeting. When the tubular reabsorption of a LMWP can be prevented, the protein will be excreted in the urine. In this way lysozyme (LZM) conjugates might also be
de Zeeuw, D; id_orcid, Pharmaceutics, Kok, RJ, Kok, Robbert J., Sub Drug delivery, Moolenaar, Frits, Moolenaar, F, de Zeeuw, D, de Zeeuw, Dick, Meijer, DKF, Haas, Marijke, Haas, M, Meijer, Dirk K.F.   +12 more
core   +1 more source